SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
NEW YORK, March 15, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased ReWalk Robotics Ltd. (NASDAQ:RWLK) securities pursuant and/or traceable to the Company’s Stock Offering on or about September 12, 2014.
Click here to learn about the case: http://www.wongesq.com/pslra/rewalk-robotics. There is no cost or obligation to you.
According to the complaint, the Registration Statement and Prospectus issued in connection with the Initial Public Offering failed to disclose material information, including that ReWalk was unprepared and/or unable to comply with “special controls” requirements or to provide the U.S. Food and Drug Administration with a post-market surveillance study as required by the FDA for the Company to maintain ongoing sales of its products.
If you suffered a loss in ReWalk you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/rewalk-robotics.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
